Your browser doesn't support javascript.
loading
Nanoparticulate chitosan-TNF-α-VLPs activate mast cells and enhance adaptive immunity induced by foot-and-mouth disease virus-like particles in mice.
Bai, Ruoman; Li, Mingzhu; Tian, Zhanyun; Hu, Yiming; An, Manxin; Yuan, Wanzhe; Li, Limin.
Afiliación
  • Bai R; College of Veterinary Medicine, Hebei Agricultural University, Baoding, Hebei 071000, China.
  • Li M; College of Veterinary Medicine, Hebei Agricultural University, Baoding, Hebei 071000, China.
  • Tian Z; College of Veterinary Medicine, Hebei Agricultural University, Baoding, Hebei 071000, China.
  • Hu Y; College of Veterinary Medicine, Hebei Agricultural University, Baoding, Hebei 071000, China.
  • An M; College of Veterinary Medicine, Hebei Agricultural University, Baoding, Hebei 071000, China.
  • Yuan W; College of Veterinary Medicine, Hebei Agricultural University, Baoding, Hebei 071000, China; Veterinary Biological Technology Innovation Centre of Hebei Province, Baoding, Hebei 071000, China.
  • Li L; College of Veterinary Medicine, Hebei Agricultural University, Baoding, Hebei 071000, China; Veterinary Biological Technology Innovation Centre of Hebei Province, Baoding, Hebei 071000, China. Electronic address: lilimin03@hebau.edu.cn.
Vet Immunol Immunopathol ; 264: 110662, 2023 Oct.
Article en En | MEDLINE | ID: mdl-37862872
ABSTRACT
Chitosan nanoparticulate vaccines have attracted considerable attention to potentiate immune responses. A chitosan-TNF-α-VLPs nanoparticle vaccine against foot-and-mouth disease virus (FMDV) prepared though inotropic gelation method and whether this nanoparticulate vaccine can activate mast cells and enhance immune responses induced by FMDV virus-like particles (VLPs) in mice was investigated. The nanoparticle was approximately spherical, and its size was approximately 200-300 nm. Following immunization via subcutaneous injection, the chitosan-TNF-α-VLPs nanoparticles could induce higher levels of FMDV-specific antibodies and stimulation index value than VLPs only (P < 0.01) and had similar levels to commercial vaccine group and VLPs+adjuvant group (P > 0.05). No significant differences were observed in the concentrations of IL-4, IFN-γ and IL-10 among the chitosan-TNF-α-VLPs group, VLPs+adjuvant group and commercial vaccine group (P > 0.05). Of note, the chitosan-TNF-α-VLPs nanoparticles can effectively activate mast cells in lymph nodes. These results indicated that the chitosan-TNF-α-VLPs nanoparticles can enhance both humoral and cell-mediated immunity, and both Th1 and Th2 responses, even activate mast cells, demonstrating that chitosan-TNF-α nanoparticles are potential as a vaccine adjuvant to enhance immune responses induced by FMDV-VLPs.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacunas / Vacunas Virales / Virus de la Fiebre Aftosa / Quitosano / Vacunas de Partículas Similares a Virus / Fiebre Aftosa Límite: Animals Idioma: En Revista: Vet Immunol Immunopathol Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacunas / Vacunas Virales / Virus de la Fiebre Aftosa / Quitosano / Vacunas de Partículas Similares a Virus / Fiebre Aftosa Límite: Animals Idioma: En Revista: Vet Immunol Immunopathol Año: 2023 Tipo del documento: Article País de afiliación: China